Targeting downstream effectors of epidermal growth factor receptor/HER2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonists.

@article{Johnston2006TargetingDE,
  title={Targeting downstream effectors of epidermal growth factor receptor/HER2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonists.},
  author={Stephen R. D. Johnston},
  journal={International journal of gynecological cancer : official journal of the International Gynecological Cancer Society},
  year={2006},
  volume={16 Suppl 2},
  pages={543-8}
}
In breast cancer, there is an increasing recognition of the pivotal role played by the epidermal growth factor receptor (EGFR) and HER2 together with the various downstream signal transduction pathways, in particular the Ras/Raf/Mek/erk1/2 pathway that regulates cell proliferation together with the phosphatidylinositol-3-OH kinase (PI3K)/Akt/mTOR pathway that is implicated in cell survival. While monoclonal antibodies and small molecule tyrosine kinase inhibitors targeted against EGFR/HER2 are… CONTINUE READING